Daxor Corporation’s BVA-100® Test Used to Guide Treatment In COVID-19 Patient
Daxor Corporation - Closed End Fund (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: GlobeNewswire
New Clinical Protocol for Volume-Guided Therapy Helps Combat Coronavirus NEW YORK, March 20, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the first use of its BVA-100 test to guide volume treatment in a patient infected with the COVID-19 virus. The company also announced the release of a clinical protocol for fluid guidance when utilizing the BVA-100 diagnostic test for COVID-19 patients developed by leading medical experts. Dr. Henry Cremisi, a lead author on the clinical protocol titled, “A Protocol for Volume-Guided Therapy for Critical Care of COVID-19 Patients,” commented, “In my clinical experience, BVA has been most useful in circumstances that are challenging with respect to volume management, as well as disorders of oxygen-carrying status including anemias and polycythemia. In the particular setting of multi-org
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation - Closed End Fund news events
Weekly update
A roundup of the hottest topics
DXR
News
- New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion [Yahoo! Finance]Yahoo! Finance
- New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of CongestionGlobeNewswire
- DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100™) [Yahoo! Finance]Yahoo! Finance
- DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)GlobeNewswire
- Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital [Yahoo! Finance]Yahoo! Finance
DXR
Sec Filings
- 4/3/24 - Form 40-17F2
- 4/3/24 - Form 40-17F2
- 4/3/24 - Form 40-17F2
- DXR's page on the SEC website